Collegium Pharmaceutical (STU:354) 3-Year Revenue Growth Rate : 15.40% (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Collegium Pharmaceutical 3-Year Revenue Growth Rate?

Collegium Pharmaceutical's Revenue per Share for the three months ended in Mar. 2024 was €3.22.

During the past 12 months, Collegium Pharmaceutical's average Revenue per Share Growth Rate was -19.80% per year. During the past 3 years, the average Revenue per Share Growth Rate was 15.40% per year. During the past 5 years, the average Revenue per Share Growth Rate was 10.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 11 years, the highest 3-Year average Revenue per Share Growth Rate of Collegium Pharmaceutical was 399.90% per year. The lowest was -7.50% per year. And the median was 15.60% per year.

Competitive Comparison of Collegium Pharmaceutical's 3-Year Revenue Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Collegium Pharmaceutical's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Collegium Pharmaceutical's 3-Year Revenue Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Collegium Pharmaceutical's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Collegium Pharmaceutical's 3-Year Revenue Growth Rate falls into.

Collegium Pharmaceutical 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Collegium Pharmaceutical (STU:354) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Collegium Pharmaceutical 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Collegium Pharmaceutical's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Collegium Pharmaceutical (STU:354) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Collegium Pharmaceutical Inc (STU:354) » Definitions » 3-Year Revenue Growth Rate

Comparable Companies

Traded in Other Exchanges

COLL:USA 354:Germany

Address

100 Technology Center Drive, Stoughton, MA, USA, 02072

Website

https://www.collegiumpharma.com

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release & immediate-release formulations of tapentadol.

Collegium Pharmaceutical (STU:354) Headlines

No Headlines